# Akums Drugs and Pharmaceuticals (NSE: AKUMS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AKUMS · Pivot · prices to 22 Oct 2026

Akums Drugs and Pharmaceuticals (NSE: AKUMS) closed at ₹690.85 on 22 Oct 2026, down 0.17% on the day. With a market capitalisation of ₹10,874 Cr, it ranks 533rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 41.5× trailing earnings, against a return on equity of 7.7% in FY26. Over the past year the share price has risen 50.2%. Its 52-week range is ₹409.30 (21 Jan 2026) to ₹838.80 (23 Sep 2026); the last close is 17.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹338 Cr (+2.9% year on year) and net profit ₹15 Cr (−44.9%), on a standalone basis. Promoters held 75.26% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹690.85 |
| Market cap | ₹10,874 Cr |
| P/E (trailing) | 41.5 |
| ROE | 7.7% (FY26) |
| ROCE | 11.4% (FY26) |
| Debt to equity | 0.02 |
| 52-week high | ₹838.80 (23 Sep 2026) |
| 52-week low | ₹409.30 (21 Jan 2026) |
| 1-year return | +50.2% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹338 Cr | +2.9% | ₹15 Cr | −44.9% | ₹0.99 |
| Q3 FY26 | ₹369 Cr | +9.2% | ₹28 Cr | −31.7% | ₹1.84 |
| Q2 FY26 | ₹309 Cr | −5.8% | ₹23 Cr | −53.4% | ₹1.53 |
| Q1 FY26 | ₹332 Cr | +4.8% | ₹45 Cr | +7.1% | ₹2.93 |
| Q4 FY25 | ₹329 Cr | +10.2% | ₹28 Cr | — | ₹1.80 |
| Q3 FY25 | ₹337 Cr | −11.9% | ₹41 Cr | +40.3% | ₹2.69 |
| Q2 FY25 | ₹328 Cr | −26.5% | ₹50 Cr | −4.5% | ₹3.38 |
| Q1 FY25 | ₹317 Cr | +0.5% | ₹42 Cr | — | ₹2.93 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹4,118 Cr | ₹344 Cr |
| FY24 | ₹4,178 Cr | ₹1 Cr |
| FY23 | ₹3,655 Cr | ₹98 Cr |
| FY22 | ₹3,672 Cr | −₹251 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 75.26%
- Foreign institutions: 1.91%
- Domestic institutions: 13.44%
- Non-institutions: 6.66%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [CORONA Remedies](https://app.pivotnow.in/stock/CORONA) | ₹2,024.70 | ₹12,360 Cr | 66.8 | 24.8% |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,245 Cr | 43.9 | — |
| [Sudeep Pharma](https://app.pivotnow.in/stock/SUDEEPPHRM) | ₹984.90 | ₹11,124 Cr | 66.2 | — |
| [Metropolis Healthcare](https://app.pivotnow.in/stock/METROPOLIS) | ₹532.25 | ₹11,035 Cr | 57.9 | — |
| [Park Medi World](https://app.pivotnow.in/stock/PARKHOSPS) | ₹220.45 | ₹9,522 Cr | 32.1 | — |
| [Blue Jet Healthcare](https://app.pivotnow.in/stock/BLUEJET) | ₹499.60 | ₹9,456 Cr | 35 | — |

## Questions and answers

### What is the share price of Akums Drugs and Pharmaceuticals today?

Akums Drugs and Pharmaceuticals (NSE: AKUMS) last closed at ₹690.85 on 22 Oct 2026. Its 52-week high is ₹838.80 and its 52-week low is ₹409.30.

### What is the market cap of Akums Drugs and Pharmaceuticals?

Akums Drugs and Pharmaceuticals' market capitalisation is ₹10,874 Cr (₹10,874 Cr) at the 22 Oct 2026 close, ranking 533rd among the NSE companies Pivot tracks.

### What is the P/E ratio of Akums Drugs and Pharmaceuticals?

Akums Drugs and Pharmaceuticals trades at a trailing P/E of 41.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 57.9.

### What is the ROE and ROCE of Akums Drugs and Pharmaceuticals?

Return on equity was 7.7% in FY26 and return on capital employed was 11.4% in FY26 (consolidated figures).

### Is Akums Drugs and Pharmaceuticals a debt-free company?

Akums Drugs and Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.

### What were Akums Drugs and Pharmaceuticals' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Akums Drugs and Pharmaceuticals reported revenue of ₹338 Cr, +2.9% year on year, and net profit of ₹15 Cr, −44.9% year on year.

### How has Akums Drugs and Pharmaceuticals stock performed over the last year?

Akums Drugs and Pharmaceuticals' share price has risen 50.2% over the past year, −0.7% over three months and −15.9% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Akums Drugs and Pharmaceuticals?

As of 30 Jun 2026: promoters 75.26%, foreign institutions 1.91%, domestic institutions 13.44%, non-institutions 6.66%.

### Who are Akums Drugs and Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Akums Drugs and Pharmaceuticals by market cap are CORONA Remedies, Rainbow Childrens Medicare, Sudeep Pharma, Metropolis Healthcare, Park Medi World and Blue Jet Healthcare.

### Is Akums Drugs and Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Akums Drugs and Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AKUMS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.